Womens Black Leather Converse Shoes
the development of cancers that might have been preventable with treatment.To help a woman and her doctor make a more informed decision about her DCIS treatment, Genomic Health developed theOncotype DXDCIS Score to provide more precise information about her individual risk of a recurrence of eitherDCIS or invasive breast cancer by looking at 12 genes within a tumor sample to reveal the aggressiveness of the disease. A clinical decision impact study recently presented at ASCO demonstrated that the Oncotype DX DCIS Score results changed treatment recommendations for one out of three patients with DCIS, highlighting the need for optimizing treatment of this non invasive form of breast disease.Genomic Health, Inc. (NASDAQ: GHDX) is the world leading provider of genomic based diagnostic tests that address both the overtreatment and optimal treatment of early stage cancer, one of the greatest issues in healthcare today.This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential benefits of the company tests for patients with DCIS; limitations of current treatment options;the company expectations regarding reporting study results; the attributes and focus of the company product pipeline; the applicability of clinical study results to actual outcomes; the ability of any potential tests the company may develop to optimize cancer treatment; and the ability of the company to develop and commercialize additional tests in the future. Forward looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company tests; the full results of the clinical study; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests and expand into new markets domestically and internationally; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; the company ability to obtain capital when needed and the other risks set forth in the company filings with the Securities and Exchange Commission, including the risks set forth in the company quarterly report on Form 10 Q for the quarter ended March 31, 2014. These forward looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward looking statements.NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc.Amarillo, TX More people are asking the police to wear body cameras especially after the recent coverage on officers using excessive force.Local reaction to new drug detecting nail polishLocal reaction to new drug detecting nail polishUpdated: Saturday, August 30 2014 5:03 AM EDT2014 08 30 09:03:49 GMTYou may have heard about a new line of nail polish that claims to detect date rape drugs in people's drinks. NewsChannel 10 spoke with a Professional Counselor at WT to find out what benefits or drawbacks this new product may have.You may have heard about a new line of nail polish that claims to detect date rape drugs in people's drinks. NewsChannel 10 spoke with a Professional Counselor at WT to find out what benefits or drawbacks this new product may have.Amarillo ISD opens a bakery to meet new healthy school meal requirementsAmarillo ISD opens a bakery to meet new healthy school meal requirementsUpdated: Saturday, August 30 2014 5:01 AM EDT2014 08 30 09:01:21 GMTAmarillo, TX Panhandle students now have healthier choices when it comes to school cooked meals because of new federal requirements.Amarillo, TX Panhandle students now have healthier choices when it comes to school cooked meals because of new federal requirements.New wheat disease tool helps alert producers and consumersNew wheat disease tool helps alert producers and consumersAmarillo, TX As our wheat fields become infected with viruses, the cost of keeping it under control can affect the prices we see at Converse All Star Amazon Uk
Health and the Ontario DCIS Study Group are submitting the results from this study for presentation at the 2014 San Antonio Breast Cancer Symposium in December. "Our landmark study, analyzing an unprecedented collection of DCIS tissue samples representative of a contemporary patient population, confirms that the Oncotype DX test can help individualize treatment decisions for this pre invasive type of breast cancer."Genomic Health researchers collaborated with the Ontario DCIS Study Group to examine a population based cohort of more than 1,200 DCIS patient tumor samples collected from patients diagnosed with DCIS between 1994 and 2003, including both patients treated with surgery alone and patients treated with surgery plus radiation. Most women with DCIS who receive breast conserving surgery without standard radiotherapy will not develop a local recurrence. However, an estimated 80 percent of these women currently receive additional treatments that may Womens Black Leather Converse Shoes not be necessary, while other women may not appropriately receive more aggressive treatment resulting in Converse Shoes Buy Online
Information contained on this page is provided by an independent third party content provider. WorldNow and this Station make no warranties or representations in connection therewith.REDWOOD CITY, Calif., June 11, 2014 /PRNewswire/ Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from a second large, independent clinical validation study of Oncotype DX in patients with a pre invasive form of breast cancer, also known as DCIS (ductal carcinoma in situ). The study, conducted by the Ontario DCIS Study Group in Canada, met its primary endpoint by demonstrating that the Oncotype DX DCIS Score predicts the risk of local recurrence, defined as either the development of a new invasive breast cancer or the recurrence of DCIS in the same breast.Representing the largest genomic study in DCIS to date, these results confirm and extend the conclusions of the previously published validation study performed by the ECOG ACRIN Cancer Research Group. Additionally, for the first time, the Oncotype DX DCIS Score predicted the risk of local recurrence in a group of patients treated with radiation therapy in clinical practice. Genomic Converse Deep Bordeaux
the grocery store.Amarillo, TX As our wheat fields become infected with viruses, the cost of keeping it under control can affect the prices we see at the grocery store.
Genomic Health Announces Positive Topline Results of Second Large
Womens Black Leather Converse Shoes
Monogram Lv Belt